Literature DB >> 24406620

Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies.

Yan Deng1, Chi Chiu Wang2, Kwong Wai Choy1, Quan Du3, Jiao Chen2, Qin Wang4, Lu Li2, Tony Kwok Hung Chung2, Tao Tang5.   

Abstract

During recent decades there have been remarkable advances in biology, in which one of the most important discoveries is RNA interference (RNAi). RNAi is a specific post-transcriptional regulatory pathway that can result in silencing gene functions. Efforts have been done to translate this new discovery into clinical applications for disease treatment. However, technical difficulties restrict the development of RNAi, including stability, off-target effects, immunostimulation and delivery problems. Researchers have attempted to surmount these barriers and improve the bioavailability and safety of RNAi-based therapeutics by optimizing the chemistry and structure of these molecules. This paper aimed to describe the principles of RNA interference, review the therapeutic potential in various diseases and discuss the new strategies for in vivo delivery of RNAi to overcome the challenges.
Copyright © 2013 Elsevier B.V. All rights reserved.

Keywords:  Gene-silencing; RNA interference; RNAi delivery; Therapeutics

Mesh:

Substances:

Year:  2014        PMID: 24406620     DOI: 10.1016/j.gene.2013.12.019

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  88 in total

Review 1.  Gene-targeting pharmaceuticals for single-gene disorders.

Authors:  Arthur L Beaudet; Linyan Meng
Journal:  Hum Mol Genet       Date:  2015-11-30       Impact factor: 6.150

Review 2.  RNA-targeted Therapeutics for ALS.

Authors:  Linga V Reddy; Timothy M Miller
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

3.  Translation efficiency of mRNAs is increased by antisense oligonucleotides targeting upstream open reading frames.

Authors:  Xue-Hai Liang; Wen Shen; Hong Sun; Michael T Migawa; Timothy A Vickers; Stanley T Crooke
Journal:  Nat Biotechnol       Date:  2016-07-11       Impact factor: 54.908

4.  [Construction and verification of anti-MM scFv-tP fusion protein expression vector].

Authors:  Hao Wang; Yi-Fei Yang; Wei Wang; Bing Guan; Meng Xun; Hai Zhang; Zi-Ling Wang; Yong Zhao
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-09-20

Review 5.  Beyond traditional pharmacology: new tools and approaches.

Authors:  E V Gurevich; V V Gurevich
Journal:  Br J Pharmacol       Date:  2015-06-10       Impact factor: 8.739

Review 6.  Bioengineered non-coding RNA agent (BERA) in action.

Authors:  Zhijian Duan; Ai-Ming Yu
Journal:  Bioengineered       Date:  2016-07-14       Impact factor: 3.269

7.  Overcoming cisplatin resistance in non-small cell lung cancer with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticles.

Authors:  Ana Vanessa Nascimento; Amit Singh; Hassan Bousbaa; Domingos Ferreira; Bruno Sarmento; Mansoor M Amiji
Journal:  Acta Biomater       Date:  2016-09-30       Impact factor: 8.947

Review 8.  Tumor-associated macrophages and anti-tumor therapies: complex links.

Authors:  Cristina Belgiovine; Maurizio D'Incalci; Paola Allavena; Roberta Frapolli
Journal:  Cell Mol Life Sci       Date:  2016-03-08       Impact factor: 9.261

Review 9.  Exosomal miRNAs: novel players in viral infection.

Authors:  Javid Sadri Nahand; Maryam Mahjoubin-Tehran; Mohsen Moghoofei; Mohammad Hossein Pourhanifeh; Hamid Reza Mirzaei; Zatollah Asemi; Alireza Khatami; Farah Bokharaei-Salim; Hamed Mirzaei; Michael R Hamblin
Journal:  Epigenomics       Date:  2020-02-25       Impact factor: 4.778

Review 10.  Development of Therapeutics for C9ORF72 ALS/FTD-Related Disorders.

Authors:  Maria Sara Cipolat Mis; Simona Brajkovic; Francesco Tafuri; Nereo Bresolin; Giacomo P Comi; Stefania Corti
Journal:  Mol Neurobiol       Date:  2016-06-28       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.